Innoviva is a company with a portfolio of royalties that include respiratory assets. The company's Long-Acting Beta2 Agonist (LABA) collaboration has developed the combination products: RELVAR? /BREO? ELLIPTA?, a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF); ANORO? ELLIPTA?, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, VI; and RELEGY? ELLIPTA? (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA and LABA.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.